Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of BEY2153 in Healthy Volunteers
NCT04476303Phase 1Completed
- Sponsor
- BeyondBio Inc.
- Start
- Aug 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BEY2153 in Alzheimer's disease (AD) (3 cohorts), sponsored by BeyondBio Inc. Primary endpoints: Maximum observed plasma concentration, Area Under the Curve and 3 more. Started Aug 2020; status: completed.
02
Drugs
BEY2153
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04476303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476303.